Varian Medical Systems — Corporate Update (January 2018)
33 slides from Varian Medical Systems's corporate update, Jan 11, 2018
Slide 1: New revenue accounting standard (ASC 606) and FY18 guidance
New revenue accounting standard (ASC 606) and FY18 guidance January 11, 2018 Gary E. Bischoping Jr., Chief Financial Officer Magnus Momsen, Chief Accounting Officer J. Michael Bruff, Vice President Investor Relations
Slide 2: Forward-Looking Statements
FORWARD - LOOKING STATEMENTS Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Statements concerning industry outlook, including growth drivers, future trends in cancer incidence and
Slide 3: Agenda
New revenue accounting standard (ASC 606) Change in service orders policy Fiscal years 2016 and 2017 Adjusted Key Earnings Financial Metrics FY18 guidance (translation) Q&A Appendix: Financial Metrics 3 Agenda
Slide 4: New revenue accounting standard (ASC 606)
New revenue accounting standard (ASC 606) 4
Slide 5: New revenue accounting standard (ASC 606)
New revenue accounting standard (ASC 606) Step 1 Identify the contracts with the customer Step 2 Identify the separate performance obligations in the contract Step 3 Determine the transaction price Step 5 Recognize revenue when (or as) the entity satisfies a performance obligation 5 Step 4 Allocate
Slide 6: What does not change, what changes, what are the impacts
What does not change? • Economics of the overall business; cash and net operating cash flows • Operating expenses, including commissions expense • Non - GAAP reconciling items • Customer billings • Customer relationships What changes? • Revenues and gross margin related to contingent payments, softw
Slide 7: Contingent Payment Example Financial Impact
Contingent Payment Example Financial Impact Both examples have a hardware sale for $2,000, of which $1,900 is the fair value of the hardware and $100 is the fair value of the installation service; hardware cost of $1,000 and installation cost of $75. Example 1 • Payment terms 80% on machine delivery
Slide 8: VSOE Example Financial Impact
VSOE Example Financial Impact 8 Example Three software products (Product A, B & C) sold together with a fair value of $250 each and cost of $50 each Software Product A & B have VSOE, Product C does not Software Products A and B are delivered in P1 and Product C is delivered in P2 What changed? VSOE
Slide 9: Software Extended Payment Example Financial Impact
Software Extended Payment Example Financial Impact 9 Example Software system sold for $1,000, cost of $200, with payment terms as follows: • $250k due on acceptance • $250K due 1 year after acceptance • $250K due 2 years after acceptance • $250K due 3 years after acceptance What changed? Payment ter
Slide 10: Other Performance Obligations Example Financial Impact
Other Performance Obligations Example Financial Impact 10 Example Equipment sold for $2,000 which includes service - type warranties with a fair value of $50 and training with a fair value of $40 • Cost of the equipment $1,100 (excluding service - type warranties and training) • Cost of service - ty
Slide 11: FY17 and FY16 Revenue prior to new revenue standard
$900 $1,200 $1,500 $1,800 $2,100 $2,400 $2,700 FY17 Restated to prior years Recognized in current year Other, net FY17 VSOE Contingent Revenue (Terms) $1,500 $1,800 $2,100 $2,400 $2,700 FY16 Restated to prior years Recognized in current year Other, net FY16 VSOE Contingent Revenue (Terms) FY17 and F
Slide 12: FY17 and FY16 Gross Margin prior to new revenue standard
$0 $200 $400 $600 $800 $1,000 $1,200 FY17 Restated to prior years Recognized in current year Other, net FY17 VSOE Contingent Revenue (Terms) $0 $200 $400 $600 $800 $1,000 $1,200 FY16 Restated to prior years Recognized in current year Other, net FY16 VSOE Contingent Revenue (Terms) FY17 and FY16 Gros
Slide 13: Change in Service Orders Policy
Change in Service Orders Policy
Slide 14: Total Varian: Change in Gross Orders Policy Impact to Gross Orders and Backlog
Total Varian : Change in Gross Orders Policy Impact to Gross Orders and Backlog Non - GAAP Investor Metrics 14 Total Varian ($M) 2015 2016 2017 Gross orders Prior orders $3,017 $2,829 $3,135 Y/Y -6% 11% Change in deferred revenue ($42) ($22) ($59) New orders $2,975 $2,807 $3,076 Y/Y -6% 10% Backlog
Slide 15: Oncology: Change in Gross Orders Policy Impact to Gross Orders and Backlog
Oncology : Change in Gross Orders Policy Impact to Gross Orders and Backlog Non - GAAP Investor Metrics 15 Oncology business unit ($M) 2015 2016 2017 Gross orders Prior orders $2,700 $2,724 $2,906 Y/Y 1% 7% Change in deferred revenue ($45) ($22) ($59) New orders $2,655 $2,702 $2,847 Y/Y 2% 5% Backlo
Slide 16: Fiscal Years 2016 and 2017 Adjusted Key Earnings Financial Metrics
Fiscal Years 2016 and 2017 Adjusted Key Earnings Financial Metrics
Slide 17: Adjusted financial summary: FY17 growth
Adjusted financial summary: FY17 growth 17 1 Gross orders and backlog reflect the net impact of the change in service order policy and ASC 606 2 Reflects ‘from continuing operations attributable to Varian’ Note: The discussion of Non - GAAP financial disclosures and the reconciliation of GAAP to Non
Slide 18: Adjusted GAAP financial summary: FY17 by quarter
Adjusted GAAP financial summary: FY17 by quarter 18 1 Gross orders and backlog reflect the net impact of the change in service order policy and ASC 606 2 Reflects ‘from continuing operations attributable to Varian’ Note: The discussion of Non - GAAP financial disclosures and the reconciliation of GA
Slide 19: FY18 Guidance (Translation)
FY18 Guidance (Translation)
Slide 20: Varian consolidated FY18 Guidance
Varian consolidated FY18 Guidance (1) These values are presented on a non - GAAP basis. We have not provided a reconciliation of non - GAAP guidance measures to the corre sponding GAAP measures on a forward - looking basis due to potential significant variability and limited visibility of the exclud
Slide 21: Q&A
Q&A
Slide 22: Appendix: Financial Metrics
Appendix: Financial Metrics
Slide 23: Non-GAAP disclosure
Non - GAAP disclosure 23 Discussion of Non - GAAP Financial Measures This presentation includes the following non - GAAP financial measures derived from our Condensed Consolidated Statements of Earnings : non - GAAP operating earnings, non - GAAP net earnings and non - GAAP net earnings per diluted
Slide 24: Adjusted GAAP to non-GAAP reconciliation
Adjusted GAAP to non - GAAP reconciliation 24 (1) Includes $1 million, $1 million, $1 million, $1 million and $5 million respectively, in cost of revenues for the periods pres ent ed. (2) Other includes acquisition - related expenses and benefits. (3) Excludes immaterial net earnings (loss) from con
Slide 25: Varian consolidated (GAAP) Key P&L Financial Metrics
Varian consolidated (GAAP) Key P&L Financial Metrics 25 Note: Unless noted otherwise, all ‘Orders’ reflects Gross Orders, all growth rates are in dollars, and year on year, and all numbers reflect continuing operations. $M Full Year Y/Y Full Year Y/Y Gross Orders $3,135 11% $3,076 10% Revenues $2,66
Slide 26: Varian consolidated (non-GAAP) Key P&L Financial Metrics
Varian consolidated (non - GAAP) Key P&L Financial Metrics Note: Unless noted otherwise, all ‘Orders’ reflects Gross Orders, all growth rates are in dollars, and year on year, and all numbers reflect continuing operations. 26 $M Full Year Y/Y Full Year Y/Y Gross Orders $3,135 11% $3,076 10% Revenues
Slide 27: Varian consolidated Key Balance Sheet and Cash Flow Metrics
Varian consolidated Key Balance Sheet and Cash Flow Metrics • No change due to adoption of ASC 606 VARIAN FISCAL 2017 $M 1Q 2Q 3Q 4Q Full Year Cash & Cash Equivalents 1 $815 $706 $658 $716 - Cash Flows from Operations 2 $82 $32 $155 $130 $399 Y/Y % 6.0% 1.0% 63.0% - 15.0% 12.0% Total Debt $607 $547
Slide 28: Oncology business unit Key Financial Metrics
Oncology business unit Key Financial Metrics 28 Note: Unless noted otherwise, all ‘Orders’ reflects Gross Orders, all growth rates are in dollars, and year on year, and all numbers reflect continuing operations. 1 Business unit operating earnings includes an allocation of corporate costs based on re
Slide 29: Particle Therapy business unit Key Financial Metrics
Particle Therapy business unit Key Financial Metrics VARIAN FISCAL 2017 $M Full Year Y/Y Gross Orders $229 120% Revenues $182 12% Product $172 13% Svcs $10 4% GM $16 - 36% % of Rev 8.8% - 661 bps Operating Earnings 1 - $96 - 115% % of Rev - 52.5% - 2,507 bps 29 Note: Unless noted otherwise, all ‘Ord
Slide 30: Total revenues by sales classification
Total revenues by sales classification 30 $M 1Q 2Q 3Q 4Q FY17 Product revenues $309 $365 $325 $403 $1,402 Y/Y -4% Service revenues $292 $298 $308 $319 $1,217 Y/Y 7% Total revenues $601 $663 $633 $722 $2,619 Y/Y 1% Product as a percentage of total revenues 51% 55% 51% 56% 54% Service as a percentage
Slide 31: Total Oncology revenues by sales classification
Total Oncology revenues by sales classification 31 $M 1Q 2Q 3Q 4Q FY17 Product revenues $282 $336 $258 $354 $1,230 Y/Y -5% Service revenues $289 $296 $306 $316 $1,207 Y/Y 7% Total revenues $571 $632 $564 $670 $2,437 Y/Y 0% Product as a percentage of Oncology Systems revenues 49% 53% 46% 53% 50% Serv
Slide 32: Total Particle Therapy revenues by sales classification
Total Particle Therapy revenues by sales classification 32 $M 1Q 2Q 3Q 4Q FY17 Product revenues $27 $29 $67 $49 $172 Y/Y 13% Service revenues $3 $2 $2 $3 $10 Y/Y 4% Total revenues $30 $31 $69 $52 $182 Y/Y 12% VPT revenues as a percentage of total revenues 5% 5% 11% 7% 7%
Slide 33: Varian
varian
Varian Medical Systems — Corporate Update (January 2018) on 6ix